Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.

BACKGROUND Vincristine (VCR) is a standard component in the treatment of childhood acute lymphoblastic leukemia (ALL). VCR cytotoxicity is primarily due to its ability to disrupt the formation of microtubules of the mitotic spindle. PATIENTS & METHODS Seventeen polymorphisms in regulatory and coding regions of genes controlling VCR targets (TUBB1, MAP4, ACTG1 and CAPG) or potentially influencing VCR levels (ABCB1 and CYP3A5) were investigated for an association with peripheral neuropathy and outcome in childhood ALL patients. RESULTS High-grade neurotoxicity was more frequent in carriers of the A allele of synonymous (Ala310) G to A (rs1135989) variation in the ACTG1 gene. Substitution (rs4728709) in the promoter of the ABCB1 gene had a protective effect against lower grade neurotoxicity and C to A variation (rs3770102) located 17 nucleotides upstream from the transcription start site had a protective effect against high-grade neurotoxicity. Patients with the ABCB1 3435TT genotype had lower event-free survival; the association with event-free survival was not supported by the analysis in the replication patient set. CONCLUSION The polymorphisms in the ACTG1, CAPG and ABCB1 genes may modulate VCR-related neurotoxicity, whereas the risk of relapse seems not to be affected by the genes of the VCR pathway.

[1]  I. Brukner,et al.  Bim Polymorphisms: Influence on Function and Response to Treatment in Children with Acute Lymphoblastic Leukemia , 2013, Clinical Cancer Research.

[2]  M. Relling,et al.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Cheng Cheng,et al.  Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. , 2012, Blood.

[4]  D. Neuberg,et al.  ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. , 2011, Blood.

[5]  N. André,et al.  Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases , 2011, Cancer Chemotherapy and Pharmacology.

[6]  N. André,et al.  Impact of plasma and intracellular exposure and CYP3A4, CYP3A5, and ABCB1 genetic polymorphisms on vincristine-induced neurotoxicity , 2011, Cancer Chemotherapy and Pharmacology.

[7]  Jingbo Wang,et al.  An update on ABCB1 pharmacogenetics: insights from a 3D model into the location and evolutionary conservation of residues corresponding to SNPs associated with drug pharmacokinetics , 2011, The Pharmacogenomics Journal.

[8]  S. Hall,et al.  Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia , 2011, Pediatric blood & cancer.

[9]  C. Pui,et al.  Biology, risk stratification, and therapy of pediatric acute leukemias: an update. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Maria Kavallaris,et al.  Microtubules and resistance to tubulin-binding agents , 2010, Nature Reviews Cancer.

[11]  M. D. Den Boer,et al.  Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. , 2010, Leukemia research.

[12]  D. Neuberg,et al.  Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) , 2009, Leukemia.

[13]  M. Krajinovic,et al.  Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. , 2009, Blood.

[14]  J. Vandekerckhove,et al.  The actin-capping protein CapG localizes to microtubule-dependent organelles during the cell cycle. , 2009, Biochemical and biophysical research communications.

[15]  D. Shen,et al.  MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents , 2009, Cancer Chemotherapy and Pharmacology.

[16]  Jennifer B Dennison,et al.  Effect of CYP3A5 Expression on Vincristine Metabolism with Human Liver Microsomes , 2007, Journal of Pharmacology and Experimental Therapeutics.

[17]  D. Neuberg,et al.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.

[18]  Lippincott-Schwartz,et al.  Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .

[19]  P. Gunning,et al.  Alterations in γ-Actin and Tubulin-Targeted Drug Resistance in Childhood Leukemia , 2006 .

[20]  Jennifer B Dennison,et al.  SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5 , 2006, Drug Metabolism and Disposition.

[21]  Maria Kavallaris,et al.  Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia – An in vivo study , 2006, Proteomics.

[22]  William E. Evans,et al.  Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy , 2006, Nature Reviews Cancer.

[23]  P. Smolewski,et al.  Multi-drug transporter MDR1 gene polymorphism and prognosis in adult acute lymphoblastic leukemia. , 2005, Pharmacological reports : PR.

[24]  F. Berrino,et al.  Childhood cancer survival trends in Europe: a EUROCARE Working Group study. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Cheng Cheng,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. , 2004, Blood.

[26]  W. Młynarski,et al.  Functional C3435T polymorphism of MDR1 gene: an impact on genetic susceptibility and clinical outcome of childhood acute lymphoblastic leukemia , 2004, European journal of haematology.

[27]  David B. Goldstein,et al.  Pharmacogenetics goes genomic , 2003, Nature Reviews Genetics.

[28]  P. Hains,et al.  Proteome Analysis of Vinca Alkaloid Response and Resistance in Acute Lymphoblastic Leukemia Reveals Novel Cytoskeletal Alterations* , 2003, Journal of Biological Chemistry.

[29]  Conrad C. Huang,et al.  Sequence diversity and haplotype structure in the human ABCB1 (MDR1, multidrug resistance transporter) gene. , 2003, Pharmacogenetics.

[30]  T. Efferth,et al.  Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. , 2003, International journal of oncology.

[31]  T. Rebbeck,et al.  CYP3A genotypes and treatment response in paediatric acute lymphoblastic leukaemia , 2003, British journal of haematology.

[32]  Y. Cheung,et al.  Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. , 2003, Pharmacogenetics.

[33]  M. Krajinovic,et al.  Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. , 2002, Blood.

[34]  M. Kasuga,et al.  Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects , 2002, Clinical pharmacology and therapeutics.

[35]  M. Kavallaris,et al.  Multiple microtubule alterations are associated with Vinca alkaloid resistance in human leukemia cells. , 2001, Cancer research.

[36]  R. Kim,et al.  Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.

[37]  P. Donnelly,et al.  A new statistical method for haplotype reconstruction from population data. , 2001, American journal of human genetics.

[38]  Ann Daly,et al.  Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression , 2001, Nature Genetics.

[39]  R. Gelber,et al.  Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.

[40]  W. Evans,et al.  Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia , 2000, Leukemia.

[41]  D. Labuda,et al.  Rapid detection of CYP1A1, CYP2D6, and NAT variants by multiplex polymerase chain reaction and allele-specific oligonucleotide assay. , 1999, Analytical biochemistry.

[42]  K. Kwiatkowska,et al.  Effects of CapG overexpression on agonist-induced motility and second messenger generation , 1995, The Journal of cell biology.

[43]  S. D. de Graaf,et al.  Vincristine disposition in children with acute lymphoblastic leukemia. , 1995, Medical and pediatric oncology.

[44]  I. Roninson,et al.  An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene , 1988, Cell.

[45]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[46]  T. Tsuruo,et al.  Characteristics of vincristine resistance in vincristine resistant human myelogenous leukemia K562. , 1986, Anticancer research.

[47]  P. Gunning,et al.  Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia. , 2006, Journal of the National Cancer Institute.

[48]  M. Schrappe,et al.  GSTP1 and MDR1 Genotypes and Central Nervous System Relapse in Childhood Acute Lymphoblastic Leukemia , 2005, International journal of hematology.

[49]  W. Kamps,et al.  Vincristine pharmacokinetics after repetitive dosing in children , 1999, Cancer Chemotherapy and Pharmacology.

[50]  H. Niitani,et al.  [Antimicrotubule agents]. , 1993, Gan to kagaku ryoho. Cancer & chemotherapy.

[51]  J. Endicott,et al.  The biochemistry of P-glycoprotein-mediated multidrug resistance. , 1989, Annual review of biochemistry.

[52]  R. Amann,et al.  Predictive Identification of Exonic Splicing Enhancers in Human Genes , 2022 .